Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-2487 in Rheumatoid Arthritis
NCT05961592Phase 1Recruiting
- Sponsor
- Rise Therapeutics
- Start
- Oct 2023
- Primary completion
- Nov 2026
- Modality
- Nanoparticles, Yeast Strains, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of R-2487 in rheumatoid arthritis (RA) (3 arms), sponsored by Rise Therapeutics. Primary endpoint: Incidence and severity of adverse events at 4 weeks. Started Oct 2023; status: recruiting.
02
Drugs
R-2487
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05961592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961592.